Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-04-24
DOI
10.3389/fimmu.2020.00501
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA
- (2020) Kodandaram Pillarisetti et al. BLOOD
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploiting NK Cell Surveillance Pathways for Cancer Therapy
- (2019) Alexander Barrow et al. Cancers
- Bispecific Antibodies in the Treatment of Hematologic Malignancies
- (2019) Johannes Duell et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
- (2019) Christina L. Zuch de Zafra et al. CLINICAL CANCER RESEARCH
- Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies
- (2019) Roman H Khadka et al. Immunotherapy
- Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
- (2019) Kristina Ellwanger et al. mAbs
- Anti-GPRC5D/CD3 bispecific T cell-redirecting antibody for the treatment of multiple myeloma
- (2019) Tatsushi Kodama et al. MOLECULAR CANCER THERAPEUTICS
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
- (2019) Thomas Nerreter et al. Nature Communications
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT
- (2019) Hermann Einsele et al. BONE MARROW TRANSPLANTATION
- 2020PA Novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion
- (2019) Z Li et al. ANNALS OF ONCOLOGY
- Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
- (2019) Dennis Cooper et al. BLOOD
- Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Noopur S. Raje et al. BLOOD
- How to Train your T cells: Overcoming Immune Dysfunction in Multiple Myeloma
- (2019) Adam D Cohen et al. CLINICAL CANCER RESEARCH
- On-target restoration of a split T cell-engaging antibody for precision immunotherapy
- (2019) Agnes Banaszek et al. Nature Communications
- Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy
- (2019) Masaki Maruta et al. Scientific Reports
- A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration
- (2019) Christian M. Schürch et al. VIRCHOWS ARCHIV
- The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
- (2018) Leo Rasche et al. BLOOD
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells
- (2018) Niels van Nieuwenhuijzen et al. CANCER RESEARCH
- The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets
- (2018) Hanley N. Abramson Clinical Lymphoma Myeloma & Leukemia
- Bispecific antibodies: design, therapy, perspectives
- (2018) Sergey Sedykh et al. Drug Design Development and Therapy
- A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
- (2018) Wing Keung Chan et al. Cancer Immunology Research
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
- (2018) Remy Thomas et al. Frontiers in Immunology
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Drug resistance in multiple myeloma
- (2018) Pawel Robak et al. CANCER TREATMENT REVIEWS
- Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
- (2018) Joshua Ryan Richter et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
- (2018) Sebastian Kobold et al. Frontiers in Oncology
- Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties
- (2018) Ayse Meric Ovacik et al. mAbs
- Engineering therapeutic bispecific antibodies using CrossMab technology
- (2018) Christian Klein et al. METHODS
- Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
- (2018) Daniel G. Guy et al. Current Hematologic Malignancy Reports
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
- (2017) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
- (2017) Hongyan Liu et al. Frontiers in Immunology
- Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
- (2016) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity
- (2016) Lawrence G. Lum et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies
- (2016) V. Hoyos et al. BLOOD
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- (2016) N. Weinhold et al. BLOOD
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth
- (2016) D. M. Beauvais et al. CANCER RESEARCH
- Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
- (2016) E. Sanchez et al. CLINICAL CANCER RESEARCH
- Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- (2016) Yogesh S. Jethava et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
- (2016) JP Laubach et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- CD28 Costimulation: From Mechanism to Therapy
- (2016) Jonathan H. Esensten et al. IMMUNITY
- Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization
- (2016) Dan Chen et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
- (2016) H Suen et al. LEUKEMIA
- Genomic complexity of multiple myeloma and its clinical implications
- (2016) Salomon Manier et al. Nature Reviews Clinical Oncology
- Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
- (2016) Y Jethava et al. Blood Cancer Journal
- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma
- (2015) Jianxuan Zou et al. CANCER SCIENCE
- Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
- (2015) G. Gorgun et al. CLINICAL CANCER RESEARCH
- Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies
- (2015) Rajendra Gharbaran CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
- (2015) Thomas Köhnke et al. Journal of Hematology & Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Clinical value of molecular subtyping multiple myeloma using gene expression profiling
- (2015) N Weinhold et al. LEUKEMIA
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
- T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
- (2015) G S Laszlo et al. Blood Cancer Journal
- Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation
- (2014) Tim Luetkens et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Understanding the multiple biological aspects leading to myeloma
- (2014) E. M. Boyle et al. HAEMATOLOGICA
- CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma
- (2013) André Veillette et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Human Fc Receptor-Like 5 Binds Intact IgG via Mechanisms Distinct from Those of Fc Receptors
- (2013) A. Franco et al. JOURNAL OF IMMUNOLOGY
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
- (2013) Joseph R. Mikhael et al. MAYO CLINIC PROCEEDINGS
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
- (2013) A. F. Labrijn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance
- (2013) C Bryant et al. Blood Cancer Journal
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
- (2012) Emmet McCormack et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- scFv Antibody: Principles and Clinical Application
- (2012) Zuhaida Asra Ahmad et al. Clinical & Developmental Immunology
- Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
- (2012) Johanna Atamaniuk et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Molecular pathogenesis of multiple myeloma and its premalignant precursor
- (2012) W. Michael Kuehl et al. JOURNAL OF CLINICAL INVESTIGATION
- A c-Myc and Surface CD19 Signaling Amplification Loop Promotes B Cell Lymphoma Development and Progression in Mice
- (2012) J. C. Poe et al. JOURNAL OF IMMUNOLOGY
- FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
- (2012) K. Elkins et al. MOLECULAR CANCER THERAPEUTICS
- Monoclonal TCR-redirected tumor cell killing
- (2012) Nathaniel Liddy et al. NATURE MEDICINE
- Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma
- (2012) Karthick Raja Muthu Raja et al. PLoS One
- The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis
- (2011) Ithamar Heber Brinkman et al. Expert Opinion On Drug Safety
- A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
- (2011) K D Boyd et al. LEUKEMIA
- A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting
- (2011) Ingo Schubert et al. mAbs
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ultra High-Risk Myeloma
- (2011) H. Avet-Loiseau Hematology-American Society of Hematology Education Program
- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
- (2010) Claudia Bluemel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Bispecific Antibody-IFN 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells
- (2010) E. A. Rossi et al. CANCER RESEARCH
- Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation
- (2010) Nobuko Ishiura et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses
- (2010) Claudia Bossen et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor
- (2010) Fabienne Mackay et al. IMMUNOLOGICAL REVIEWS
- Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cells
- (2010) Jose De Salort et al. IMMUNOLOGY LETTERS
- Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma
- (2010) S. REID et al. International Journal of Laboratory Hematology
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
- (2010) R A Kyle et al. LEUKEMIA
- Bispecific antibodies for cancer therapy
- (2010) Patrick Chames et al. mAbs
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- SLAM-Family Receptors: Immune Regulators with or without SAP-Family Adaptors
- (2010) A. Veillette Cold Spring Harbor Perspectives in Biology
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
- (2009) Dharminder Chauhan et al. CANCER CELL
- APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
- (2009) Jérôme Moreaux et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- CD19: a promising B cell target for rheumatoid arthritis
- (2009) Thomas F. Tedder Nature Reviews Rheumatology
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- CD38 is constitutively expressed in the nucleus of human hematopoietic cells
- (2008) M. Orciani et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- The NKG2D receptor: sensing stressed cells
- (2008) Carlos López-Larrea et al. TRENDS IN MOLECULAR MEDICINE
- Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
- (2007) Y.-T. Tai et al. BLOOD
- The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity
- (2007) J. Lauring et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation